Current Report Filing (8-k)
November 02 2021 - 4:07PM
Edgar (US Regulatory)
0001279704
false
0001279704
2021-11-01
2021-11-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 1, 2021
CELLECTAR
BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
1-36598
|
|
04-3321804
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
100
Campus Drive, Florham Park, New Jersey 07932
(Address of principal executive offices, and zip code)
(608)
441-8120
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, par value $0.00001
|
|
CLRB
|
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 1, 2021, the
Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that,
based upon the closing bid price of the Company’s common stock (“Common Stock”) for the last 30 consecutive business
days beginning on September 20, 2021, and ending on October 29, 2021, the Company no longer meets the requirement to maintain a minimum
bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2).
In accordance with Nasdaq
Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until May 2, 2022, in which to regain compliance.
In order to regain compliance with the minimum bid price requirement, the closing bid price of the Company’s Common Stock must be
at least $1 per share for a minimum of ten consecutive business days during this 180-day period. In the event that the Company does not
regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days
if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the
Nasdaq Capital Market, with the exception of the bid price requirement, and provides written notice to Nasdaq of its intent to cure the
deficiency during this second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq
staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice
to the Company that its Common Stock will be subject to delisting.
The letter does not result
in the immediate delisting of the Company’s Common Stock from the Nasdaq Capital Market. The Company intends to monitor the closing
bid price of its Common Stock and consider its available options in the event that the closing bid price of the Company’s Common
Stock remains below $1 per share.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 2, 2021, the Company appointed Dr.
Laurence Reilly as Interim Chief Medical Officer of the Company. Dr. Reilly succeeds John Friend, MD, who is stepping down but will stay
on through mid-November to finalize the ongoing transition.
Dr. Reilly, age 39, has consulted for the Company
since early this year. Prior to joining Cellectar, he provided strategic consulting and due-diligence services to biotech companies, life
science venture capital and private equity clients, alongside serving as chief strategy & development officer to a European-based
medical device company. Prior to founding his consulting practice, Dr. Reilly served as chief scientific officer and vice president at
Avillion, a drug development company focused on the co-development and financing of pharmaceutical candidates, where he was responsible
for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer and
AstraZeneca. Dr. Reilly previously served as a clinician at Pfizer and began his industry career at Lundbeck where he served as medical
and scientific advisor overseeing investigator-initiated research, opinion leader interaction and new compound presentation. Dr. Reilly
earned his medical degree from the University of Liverpool Medical School, U.K., and a Masters Degree in Law from De Montfort University,
U.K.
Dr. Reilly has no family relationships with any
of the Company’s directors or executive officers, and he has no direct or indirect material interest in any transaction required
to be disclosed pursuant to Item 404(a) of Regulation S-K.
On April 8, 2021, the Company entered into a consulting
agreement with Dr. Reilly (the “Consulting Agreement”), pursuant to which the Company engaged Dr. Reilly to serve as an independent
consultant for the purpose of providing the Company with certain services. On November 2, 2021, the Company appointed Dr. Reilly to the
position of Interim Chief Medical Officer and as such, that Dr. Reilly would continue to serve as an independent consultant pursuant to
the Consulting Agreement for the purpose of providing the Company with certain services, including the services to be provided by Dr.
Reilly as the Company’s Interim Chief Medical Officer.
The Company’s
press release announcing the appointment of Dr. Reilly is filed as Exhibit 99.1 hereto and incorporated by reference herein.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 2, 2021
|
CELLECTAR BIOSCIENCES, INC.
|
|
|
|
|
|
By:
|
/s/ Dov Elefant
|
|
|
Name:
|
Dov Elefant
|
|
|
Title:
|
Chief Financial Officer
|
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jul 2023 to Jul 2024